Tisagenlecleucel治疗年轻急性淋巴细胞白血病移植后复发的欧洲真实世界结局决定因素
这项多中心真实世界研究纳入31个欧洲中心的220例造血干细胞移植后复发的儿童/年轻成人B-ALL患者,评估tisa-cel的结局决定因素。中位随访30.0个月,2年无事件生存率43.6%,总生存率67.2%,CAR-T失败发生率57.1%。匹配同胞供者移植、移植后早期复发及淋巴细胞清除时疾病负荷是CAR-T失败的风险因素。
要点
- 移植后早期复发(<6个月)患者2年EFS仅23.7%,OS 47.2%,显著劣于晚期复发。
- 淋巴细胞清除时MRD阴性者2年OS达81.7%,非缓解者仅55.2%。
- 匹配同胞供者移植后复发者CAR-T失败率最高(2年73.8%)。
核心结论
- 匹配同胞供者移植史、移植后早期复发及淋巴细胞清除时疾病负荷可识别HSCT后CAR-T失败高风险患者。
研究设计与样本
- 多中心真实世界研究,纳入31个欧洲中心的220例HSCT后复发的儿童/年轻成人B-ALL患者,接受tisa-cel治疗,中位随访30.0个月。
主要发现
- 2年无事件生存率43.6%,总生存率67.2%,CAR-T失败发生率57.1%。
- 匹配同胞供者移植后复发者2年OS为59.1%,低于错配供者80.2%和匹配家庭/无关供者68.3%(p=0.046);2年CAR-T失败率匹配同胞供者73.8%最高(p=0.006)。
- 移植后早期复发(<6个月)者2年EFS 23.7%、OS 47.2%,劣于晚期复发(≥6个月)者EFS 49.8%(p=0.001)、OS 73.9%(p<0.001)。
- 淋巴细胞清除时MRD阴性者2年OS 81.7%,MRD阳性者69.2%,非缓解者55.2%(p=0.003),非缓解者CAR-T失败率最高。
临床怎么用
- 对HSCT后复发患者,应评估供者类型、移植后复发时间及淋巴细胞清除时疾病负荷以分层CAR-T失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure. CAR-T for relapse after transplant from a matched sibling donor (MSD) compared to alternative donors was associated with lower 2-year-OS (MSD 59.1%, mismatched donor MMD 80.2%, matched family/unrelated donor MFD/MUD 68.3%, p = 0.046). Two-year incidence of CAR-T failure was highest for MSD (MSD 73.8%, MFD/MUD 49.7%, MMD 52.2%, p = 0.006). Patients who had relapsed early (< 6 months post HSCT) showed inferior 2-year-EFS (23.7%) and OS (47.2%) compared to patients with late relapse, ≥ 6 months after HSCT (EFS 49.8%, p = 0.001; OS 73.9%, p < 0.001). Early relapse was associated with a higher incidence of CAR-T failure and relapse after tisa-cel, particularly CD19+ relapses. Outcomes correlated with disease burden at lymphodepletion: 2-year-OS was 81.7% for MRD-, 69.2% for MRD+, and 55.2% for patients in non-remission (p = 0.003), with incidence of CAR-T failure highest in non-remission. Prior transplant from an MSD, early post-HSCT relapse, and disease burden at lymphodepletion identify patients at increased risk of CAR-T failure after HSCT.
引用
- Moser LM, Hutter M, Ahlmann M, et al. Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome. Leukemia. 2026. PMID: 42675139. doi:10.1038/s41375-026-03105-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。